Emtricitabina. Tenofovir Disoproxil Y Rilpivirina

Resumen

Alternativas con registro en Colombia

• Lamivudina Y Zidovudina
• Lamivudina Y Abacavir
• Tenofovir Disoproxil Y Emtricitabina
• Abacavir/zidovudina/lamivudina
• Efavirenz. Tenofovir Disoproxil Y Emtricitabina
• Emtricitabina. Tenofovir Disoproxil. Elvitegravir Y Cobicistat
• Lopinavir Y Ritonavir
• Lamivudina. Tenofovir Disoproxil Y Efavirenz
• Lamidubina. Abacavir Y Dolutegravir
• Darunavir Y Cobicistat
• Emtricitabina Y Tenofovir Alafenamida
• Elvitegravir. Cobicistat. Emticitabina. Tenofovir Alafenamida

Estudios clínicos principales

• Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emt
  Fase 3 · 2015 · 881 participantes · Gilead Sciences · NCT02345226 · PubMed 30101539 · PubMed 28259776
• Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive
  Fase 3 · 2015 · 632 participantes · Gilead Sciences · NCT02345252 · PubMed 30101539 · PubMed 28259777
• Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC
  Fase 3 · 2015 · 567 participantes · Gilead Sciences · NCT02469246 · PubMed 29475804 · PubMed 30932951
• BRAAVE 2020: Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of
  Fase 3 · 2018 · 496 participantes · Gilead Sciences · NCT03631732 · PubMed 34397746

Enfermedades relacionadas

• VIH

Fuentes

• Etiqueta FDA (DailyMed): emtricitabine, rilpivirine and tenofovir disoproxil fumarate
• EMA: Eviplera